Laminin & Tf and 2C5 antibod.

AS oligonucleotide, experimental therapy

Fujita et al. (2007) J Control Release 122(3):356

Caspases 3 & 8

AS oligonucleotide, experimental therapy

Gdynia et al. (2007) Mol Cancer Res 5(12):20

miR-21

AS oligonucleotide, experimental therapy

Gabriely et al. (2008) Mol Cell Biol 28(17):536

miR-21

AS oligonucleotide, experimental therapy

Shi et al. (2008) Zhonghua Yi 25(5):497

TGF-beta and

immune activation

AS oligonucleotide (NPs), experimental therapy

Schneider et al. (2008) J Neuroimmun 195(1-2):21

TGF-beta and

immune activation

AS oligonucleotide, experimental therapy

Vega et al. (2008) Future Oncol 4(3):433

Heat shock-protein 27 (Hsp27)

AS oligonucleotide, experimental therapy

Aloy et al. (2008) Int J Radiat Oncol Biol Phys 70(2):543

VEGF

AS vector, experimental therapy

Lin et al. (2008) Cancer Sci 99(12):2540

TGF-beta 2

AS oligodeoxynucleotide, clinical trial

Schlingensiepen et al. (2008) Rec Res Cancer Res 177:137

IGF-I

AS vector, clinical trial

Trojan et al. (2009) JAC 1:1

TGF-beta 2

AS oligodeoxynucleotide, clinical trial

Hau et al. (2009) Expert Rev Anticancer Ther 9(11):166

IGF BP2

AS vector, experimental therapy

Moore et al. (2009) Proc Natl Acad Sci USA 106(39):16675

CD133/

AS oligonucleotide, experimental therapy

Yao et al. (2009) Oncol Rep 22(4):781 prominin-1

EGFR

AS oligonucleotide, experimental therapy

Loew et al. Anticancrer Agents Med Chem 9(6):703

TGF-beta

AS oligodeoxynucleotide, clinical trial

Vallieres (2009) IDrugs 12(7):445

miR-21

AS oligonucleotide, experimental therapy

Li et al. (2009) Brain Res 25(1286):13

miR221/222

AS oligonucleotide, experimental therapy

Zhang et al. (2009) Int J Oncol 34(6):1653

IGF-I

AS vector, clinical trial

Trojan et al. (2010) Biomed & Pharmaother 64(8):57

miR-21

AS oligonucleotide, experimental therapy

Zhou et al. (2010) Oncol Rep 24(1):195

c-Met

AS oligonucleotide, experimental therapy

Chu et al. (2010) Oncol Rep 24(1):189

AKT2

AS oligonucleotide, experimental therapy

Zhang et al. (2010) Oncol Rep 24(1):65

EGFR

AS oligonucleotide, experimental therapy

Li et al. (2010) Oncol Rep 23(6):1585

PED/PEA-15 (ERK1/2-inter.

protein)

AS oligonucleotide, experimental therapy

Botta et al. (2010) Hum Gene Ther 21(9):1067

miR-21 & 5FU

AS oligonucleotide, experimental therapy

Ren et al. (2010) J Biomater Sci Polym Ed 21(3):303

miR-21

AS oligonucleotide, experimental therapy

Zhou et al. (2010) Lab Invest 90(2):144

EGFR

AS oligonucleotide, experimental therapy

Kang et al. (2010) J Biomed Mater Res A 93(2):585

Laminin-411

AS oligodeoxynucleotide, clinical trial

Ding et al. (2010) Proc Natl Acad Sci USA 107(42):18143

TGF-beta & T cell therapy

AS oligodeoxynucleotide, clinical trial

Dietrich et al. (2010) Curr Opin Oncol 2010; 22(6):604

Telomerase & taxifen

AS oligonucleotide, experimental therapy

Wang et al. (2010) Mol Med Report 3(6):935

VEGF

AS vector, experimental therapy

Yang et al. (2011) J Neurooncol 103(1):33

IGF-I

AS vector, clinical trial

Trojan & Anthony (2011) Curr Signal Transd Ther 6(3):411

TGF-beta

AS oligodeoxynucleotide, clinical trial

Jashinsky et al. (2011) Curr Pharm Biotechnol 12(12):220

TGF-beta

AS oligodeoxynucleotide, clinical trial

Hau et al. (2011) Curr Pharm Biotechnol 12(12):2250

PrPc

AS oligonucleotide, experimental therapy

Barbieri et al. (2011) Autophagy 2011 Aug 1; 7(8). [Epub]

miR-10b

AS oligonucleotide, experimental therapy

Sun et al. (2011) Brain Res 1389:9

uPAR

AS vector, experimental therapy

Raghu et al. (2011) Mol Cancer 10:130

microRNA-7

AS oligonucleotide, experimental therapy

Lee et al. (2011) Radiother Oncol 101(1):171

miR-221/222

AS oligonucleotide, experimental therapy

Hao et al. (2012) Oncol Rep 27(5):1504